ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization — Recruiting • Phase II • NCT07088926.
- New antibody treatment tested to prevent lung flare-ups in bronchiectasis patients with chronic bacterial infection.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA. Conditions: Bronchiectasis With Pseudomonas Aeruginosa Colonization Interventions: AZD0292, Placebo Lead Sponsor: AstraZeneca Planned Enrollment: 435 participants